Lock Down the Critical Factors in Oligo and Oligo-Conjugate Characterization with Stunner and Honeybun
Nov. 12, 2026 | 8:00 am PT, 11:00 am ET, 17:00 CET
This GEN webinar follows oligo quantification from method development through conjugate characterization.
Beyond Binder Design: AI Agents and Foundation Models for Biologics Development
Nov. 12, 2026 | 11:00 am PT, 2:00 pm ET, 20:00 CET
In this GEN webinar, Asimov’s co-founder and CEO Alec Nielsen, PhD, will show how Asimov combines bio-foundation models, AI agents, and synthetic biology to augment development workflows.
Spatial Proteomics for Precision Oncology
Nov. 16, 2026 | 8:00 am PT, 11:00 am ET, 17:00 CET
In this GEN webinar, Bernd Bodenmiller, PhD (University of Zürich), illustrates this integrated approach through two recent examples.
How Preclinical Manufacturing Can De-Risk the Path to GMP-Ready Viral Vector Programs
Nov. 17, 2026 | 8:00 am PT, 11:00 am ET, 17:00 CET
In this GEN webinar, Chris Nieder, an expert in viral vector programs, will examine how strategically designed preclinical manufacturing campaigns provide a practical foundation for GMP production.
Bridging the Translational Gap in Pancreatic Cancer Through Biology-First Modeling
Nov. 18, 2026 | 8:00 am PT, 11:00 am ET, 17:00 CET
In this GEN webinar, our expert speaker Josh Wheeler, MD, PhD, will discuss a biology-first, interpretable AI approach to understand patient tumor states and next-generation preclinical models that reproduce their biological complexity.
Single-Cell Multiomics: Phenotypic Plasticity in Colorectal Cancer Metastasis
Nov. 19, 2026 | 8:00 am PT, 11:00 am ET, 17:00 CET
In this GEN webinar, Mirjana Efremova, PhD (Queen Mary University of London) will show how these technologies can be used to analyze primary and liver-metastatic CRC patient samples to reveal cancer cell states.
Perfusion-Based mAb Production at 250 mL Scale Using ATF Technology
Dec. 03, 2026 | 8:00 am PT, 11:00 am ET, 17:00 CET
In this GEN webinar, Vivian Ott, a process intensification specialist, will present data demonstrating how a small-scale mAb perfusion process can yield comparable outcomes to large-scale bioreactors. Attendees will also hear from Repligen’s Béla Brühlmann, who will introduce the benefits of upstream process intensification.
The Organoid Odyssey: A Glimpse Into the Past, Present, and Future of hPSC-Derived 3D Models
Dec. 03, 2026 | 8:00 am PT, 11:00 am ET, 17:00 CET
In this GEN webinar, our expert speaker, Arati Naveen, PhD, will trace the foundational discoveries that shaped organoid technology as a new approach methodology (NAM), while highlighting pioneering contributions and contemporary advances.